Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
about
A physiological role of the adenosine A3 receptor: sustained cardioprotectionA2A receptors in inflammation and injury: lessons learned from transgenic animalsA new drug design targeting the adenosinergic system for Huntington's diseaseInteractions of flavones and other phytochemicals with adenosine receptorsThe A3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteinsPharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cellsA(1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouseStructure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonistsPyran Template Approach to the Design of Novel A3 Adenosine Receptor AntagonistsThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsNew approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kineticsAdenosine-enhanced ischemic preconditioning: adenosine receptor involvement during ischemia and reperfusion.Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation.Structure-based discovery of A2A adenosine receptor ligands.The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists.Polyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide.The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophagesAdenosine and ischemic preconditioning.Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptorIdentification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor.A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulationStructure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonistsN6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors.Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration.Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancersAdenosine A3 receptors: novel ligands and paradoxical effects.Click modification in the N6 region of A3 adenosine receptor-selective carbocyclic nucleosides for dendrimeric tethering that preserves pharmacophore recognition.Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure.Swelling-activated chloride channels in aqueous humour formation: on the one side and the other.Activation and Desensitization of Rat A3-Adenosine Receptors by Selective Adenosine Derivatives and Xanthine-7-Ribosides.Investigational A₃ adenosine receptor targeting agents.Inosine induces presynaptic inhibition of acetylcholine release by activation of A3 adenosine receptors at the mouse neuromuscular junction.Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species.Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives.
P2860
Q24650457-6CC0D2D7-9024-4186-A593-AB5F500CCE3FQ24652486-D603D106-F841-4B0A-9AEF-FBAEB2673208Q27335053-721A13D3-43A4-42D1-A5B1-A6AE92626FE2Q28207053-E1A09105-3BD1-4187-B4D1-3A332303B640Q28344385-F3C70C6A-5063-4AB4-B21F-C04ECA54E9CCQ28346743-3F7CB9E0-17B3-4292-B57F-08258034AC5AQ28356516-76DEC178-1EF3-42BB-8954-FE32D55DB5CCQ28368377-A72604AA-6C99-4C33-BC6C-1B7FAD1FE6F3Q28834245-1A64004E-B8D3-4E38-8A2E-28CEA0D1CFFDQ30486707-098304B2-1371-45DE-B8B2-8FFFFDAC804AQ31172470-D0A86117-7A94-4319-BA9F-63BB450A0BDAQ31833683-BB5C6D95-8B03-452E-94BE-9DC83685C603Q33523962-A753F611-AA81-4A54-BCDE-B4867850A8E4Q33560239-2093C30D-BDC5-490A-9EC9-427A411BFBB8Q33624360-054AE93C-2A61-4AB2-BB57-9C0763FFC023Q33638882-9BA876DA-4BEC-464A-A288-01DD19D9E87CQ33754704-C0B3F9A2-1ED2-4C3D-A295-E41C31241348Q33767229-EAFAA1DA-197F-43BF-AF20-541110EF1080Q33801903-6FCDA7EE-4ED8-4E3B-8958-07050E9A8384Q33894529-F3067AA6-2C9F-4384-A2B3-A9CD3EFAB7EEQ34118123-88263A08-9BBF-4C5E-8EAB-C499FB7AADDEQ34159374-21FD54C0-7305-4FCB-87ED-22B78320B014Q34676680-60F15208-2F1E-44C9-9612-05CA789D207CQ35029175-20FD17E9-9987-45A6-9C06-EF4F688375CCQ35048339-B6A9D421-1FB9-43F1-BAAE-DB695A423551Q35124859-0FADE6DD-638B-4434-AB20-571669554C86Q35133003-B59DAA07-B822-45FF-A8A8-8FE12E643AFBQ35154034-B558AAE9-E583-49D7-910A-DBB713C3F129Q35171034-C36F7799-A999-4A03-96CB-D504A69FD454Q35795478-96F19244-2D94-49CB-806D-DE44A40C05D5Q36021597-D3FA1956-765A-47F8-81E2-CEA9BA256AB7Q36146803-D9B2486D-D732-44CA-9609-6C57D19FDD26Q36316924-8B33CB72-38A2-459B-9E3B-E347C8EDDBD3Q36317172-A693823B-3BCE-4CAC-9174-641020C81F6DQ36492553-8A251038-5E31-4306-9E33-6A8C780A638EQ36661011-FE3FA972-E0B5-40DA-8B7F-61DA0C5BF5B2Q36731575-29566272-99A0-441E-95D1-B275E453B4AEQ37122701-FF14DBD1-7F26-45E5-89FF-FD2C4AFD06FCQ37461055-E5A1B287-9CD4-4923-BDF3-FD16571A3BF2Q37636314-B1DABE5F-E2B4-43AD-8D43-5E8E74C6E9C7
P2860
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@ast
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@en
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@nl
type
label
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@ast
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@en
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@nl
prefLabel
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@ast
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@en
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@nl
P2093
P2860
P1433
P1476
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists
@en
P2093
G L Stiles
K A Jacobson
P2860
P304
P356
10.1016/S0028-3908(97)00104-4
P407
P577
1997-09-01T00:00:00Z